Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 45.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,228 shares of the medical equipment provider’s stock after acquiring an additional 695 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Intuitive Surgical were worth $991,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the 2nd quarter worth approximately $26,000. Creekmur Asset Management LLC grew its holdings in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 42 shares during the period. LGT Financial Advisors LLC raised its position in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares in the last quarter. Delos Wealth Advisors LLC lifted its holdings in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. Finally, LRI Investments LLC purchased a new stake in shares of Intuitive Surgical during the 1st quarter worth $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Down 1.6 %

Intuitive Surgical stock opened at $483.32 on Wednesday. The stock has a fifty day moving average price of $465.50 and a 200 day moving average price of $423.39. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $496.18. The firm has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the company posted $1.18 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling

In other news, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $136,522.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Robert Desantis sold 1,413 shares of Intuitive Surgical stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,120 shares of company stock valued at $25,528,753. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ISRG shares. Robert W. Baird increased their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their target price for the company from $380.00 to $510.00 in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. BTIG Research raised their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Finally, Barclays boosted their target price on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.